Marlborough, MA, United States of America

Beata Sweryda-Krawiec

This inventor holds 6 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent. Top assignees: Tarveda Therapeutics, Inc., Tva (Abc), LLC. Active years: 2017-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Beata Sweryda-Krawiec. Retrieved from https://idiyas.com/inventor/beata-sweryda-krawiec

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 7)

% Patents Active = 33.3

CIPO Patents = 1 (Patent Applications = 6)

Average Co-Inventor Count = 8.7

ph-index = 2

Forward Citations = 8(Granted Patents)

Company Filing History:

5 out of 8

Tarveda Therapeutics, Inc.

Years Active: 2017-2022

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11458206 - Targeted conjugates and particles and formulations thereof (2022-10-04),

2. 11213590 - SSTR-targeted conjugates and particles and formulations thereof (2022-01-04),

3. 11160871 - SSTR-targeted conjugates and particles and formulations thereof (2021-11-02),

4. 10624967 - Targeted conjugates and particles and formulations thereof (2020-04-21),

5. 10322191 - Targeted conjugates and particles and formulations thereof (2019-06-18),

6. 9750818 - Targeted conjugates and particles and formulations thereof (2017-09-05),

Title: Beata Sweryda-Krawiec: Innovator in Targeted Therapeutics

Introduction

Beata Sweryda-Krawiec is a prominent inventor based in Marlborough, MA (US). She has made significant contributions to the field of targeted therapeutics, holding a total of 6 patents. Her work focuses on the development of nanoparticles and microparticles designed to improve the delivery and efficacy of therapeutic agents.

Latest Patents

Among her latest patents are innovative formulations that utilize targeted conjugates and particles. These formulations include nanoparticles and microparticles that contain conjugates of active agents, such as therapeutic, prophylactic, or diagnostic agents, attached to targeting moieties. These advancements aim to enhance the temporospatial delivery of active agents and improve biodistribution, particularly in the treatment of cancer and infectious diseases. Additionally, her work on SSTR-targeted conjugates and particles has shown promise in providing improved delivery and reduced toxicity for cancer treatments.

Career Highlights

Beata has worked with notable companies in the biotechnology sector, including Tarveda Therapeutics, Inc. and Tva (ABC), LLC. Her experience in these organizations has allowed her to collaborate on groundbreaking research and development projects that push the boundaries of targeted therapies.

Collaborations

Throughout her career, Beata has collaborated with esteemed colleagues, including Rajesh R Shinde and Rossitza Gueorguieva Alargova. These partnerships have contributed to her innovative work and the advancement of therapeutic technologies.

Conclusion

Beata Sweryda-Krawiec is a trailblazer in the field of targeted therapeutics, with a focus on improving treatment outcomes through innovative formulations. Her contributions continue to shape the landscape of medical science and offer hope for more effective therapies.

Profile summary based on public USPTO records.